Solving a Problem
ARTMS’ technology was founded by a group of TRIUMF scientists, including ARTMS’ current Chief Technology Officer, Dr. Paul Schaffer in 2013 to tackle projected Technetium-99m shortages after the decommissioning of the reactor at Chalk River. Once the goal of cyclotron produced Technetium-99m was achieved, ARTMS continued to innovate by developing new solid targets, streamlined processes and standard purification protocols. Eventually ARTMS Inc. was formed and has been operating as a stand-alone entity since 2016.
Expanding Partnerships & Regulatory Approval
ARTMS has since secured several rounds of funding and expanded from Technetium production to PET isotopes like Gallium-68. The latest round of funding in May 2020 has allowed ARTMS to focus on partners that need to produce large volumes of PET isotopes like Gallium-68 and Ziconium-89 used in the preparation of radiopharmaceuticals for Molecular Imaging studies, along with securing the proper regulatory approvals for this type of production and usage.
Revolutionizing Nuclear Medicine
ARTMS has forever changed the way isotopes are supplied to clinicians and patients. ARTMS’ continued innovation and partnership will help ensure that tens of thousands of patients will receive the appropriate diagnostic scan at the proper time.
The ARTMS Leadership Team
Charles S. Conroy
(Chief Executive Officer)
Charles S. Conroy is the Chief Executive Officer (CEO) of ARTMS Inc. Conroy brings to ARTMS more than 25 years of experience in the life sciences industry, including several significant senior positions within the radiopharmaceutical industry. Most recently Conroy was the General Manager of Jubilant Pharma where he was responsible for North American sales and operations. Prior to joining Jubilant, he was the Chief Operating Officer of PharmBlue LLC, a nationwide specialty pharmacy business focusing on the federal 340B drug program, retroviruses, mental and behavioral health, custom compounding, and pain management. Previously, he was the Senior Director of Pharmacy Operations managing Express Scripts’ flagship pharmacy at the Technology and Innovation Center in St. Louis, Missouri. Conroy has held a variety of roles with increasing responsibility at Amerinet (Intalere), Covidien, Eli Lilly and Nycomed Amersham (GE Healthcare). Conroy earned a Bachelors in Science, Pharmacy from Purdue University and a Masters of Business Administration from the University of Michigan. Conroy was among the first to earn his Board Certification in Nuclear Pharmacy (BCNP) and is a registered pharmacist in 17 states.
Dr. Michael Cross
(Chief Innovation Officer)
Dr. Michael Cross PhD, MBA, is the Chief Innovation Officer of ARTMS Inc. and has responsibilities that include business and product development. Dr. Cross has over 20 years of industry experience with a successful background in venture capital financing, operations and business development transactions. Cross was the co-founder/COO/CBO of OncoSec Medical, an immuno-oncology company in San Diego. Before starting OncoSec Cross was the SVP and co-lead of a $330M Canadian life sciences venture fund. He has held senior positions at Viventia Biotech, MDS Proteomics, MDS Capital and the Toronto Raptors basketball team. Cross received his PhD in physiology from the University of Toronto and completed his post-doctoral training with the Department of Defense.
Dr. Paul Schaffer
(Chief Technical Officer)
Dr. Paul Schaffer is CTO of ARTMS Inc. and Head of TRIUMF’s Life Sciences division. Dr. Schaffer came to TRIUMF in 2009 from the private sector where he worked at General Electric in upstate New York. He earned his Ph.D. in chemistry from McMaster University in 2003 and earned his B.Sc. with honours in chemistry and biochemistry from the University of British Columbia (UBC) in 1998. He is now also an adjunct professor at Simon Fraser University’s Department of Chemistry and an assistant professor in the Department of Radiology at UBC. The commendations for Schaffer are many but he is most recognized for his earnest sincerity, his positive attitude, and his ability to create teams that produce phenomenal results on short time scales. A master of his subject matter, Schaffer has transformed the TRIUMF nuclear-medicine program by focusing on core competencies, specific outcomes, and connections with industrial and commercial interests.
(Chief Commercial Officer)
Doug Gentilcore is the Chief Commercial Officer of ARTMS Inc. and leads its sales/marketing efforts. Gentilcore has over 15 years of senior level sales in global radiopharmaceutical and imaging markets. Gentilcore was President of Implerem, a consulting firm focused on strategic and commercial solutions for the nuclear medicine industry. Prior to Implerem, he was the VP of Global Sales and Business Operations at Jubilant Radiopharma where he grew the sales/business operations team from a staff of 8 to over 70. Gentilcore has also held roles of increasing responsibility at Purview-Force 3, GE Healthcare, and Pfizer. Gentilcore has a BA in Business Economics from Randolph-Macon College.
(Chief Operating Officer)
Mark Przekop, R.Ph., Chief Product Officer, leads Product Development and Commercialization at ARTMS Inc. Przekop is a commercial and operational leader with more than 30 years of pharma industry experience. Przekop worked and consulted with numerous radiopharmaceutical companies and has extensive experience in the nuclear medicine industry from both an operational and commercial perspective. Przekop is the former VP of Pharmacy Services | East and VP of Operations at Jubilant DraxImage Radiopharmacies, and also held leadership positions at GE Healthcare, Amersham Healthcare, and Mallinckrodt Medical.